Utah Medical Products (UTMD) Cash & Equivalents (2010 - 2026)

Utah Medical Products' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $87.4 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 4.9% year-over-year to $87.4 million in Q1 2026; TTM through Mar 2026 was $87.4 million, a 4.9% increase from a year earlier, with the FY2025 full-year figure at $85.8 million, up 3.35% from the prior year.
• Cash & Equivalents improved to $87.4 million in Q1 2026 per UTMD's latest filing, from $85.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $93.8 million in Q1 2024 and bottomed at $65.9 million in Q1 2022.
• The 5-year median for Cash & Equivalents is $84.3 million (2025), against an average of $82.4 million.
• Across the five-year window, Cash & Equivalents climbed 27.78% in 2023 and declined 11.17% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $75.1 million in 2022, then grew by 23.74% to $92.9 million in 2023, then fell by 10.65% to $83.0 million in 2024, then increased by 3.35% to $85.8 million in 2025, then climbed by 1.92% to $87.4 million in 2026.
• Per Business Quant, the three latest UTMD Cash & Equivalents figures stand at $87.4 million (Q1 2026), $85.8 million (Q4 2025), and $84.3 million (Q3 2025).